Panacos Pharmaceuticals, Inc. engages in the discovery and development of small molecule oral drugs for the treatment of human immunodeficiency virus (HIV) and other human viral diseases. The company’s proprietary discovery technologies, as well as its therapeutic candidate, PA-457, focus on targets in the virus life cycle, including virus fusion and virus maturation. PA-457 is a class of HIV drugs called Maturation Inhibitors with activity against HIV and is in Phase II clinical testing for HIV infection. The company has collaboration with Evotec OAI, which offers drug discovery and development services. Panacos Pharmaceuticals was formerly known as V.I. Technologies, Inc. and changed its name to Panacos Pharmaceuticals, Inc. in August 2005. The company is headquartered in Watertown, Massachusetts.